By Karen Roman ReAlta Life Sciences, Inc. said it was granted Orphan Drug Designation by the European Medicines Agency (EMA) for RLS-0071 (pegtarazimod), to treat Graft-versus-Host Disease (GvHD). The designation was supported by preliminary data from the company’s Phase 2 trial...

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG) said it received FDA and EMA clearance for GLORA-4, a global registrational Phase III trial of their Bcl-2 inhibitor lisaftoclax for first-line treatment of higher-risk myelodysplastic syndrome. The company said it is addressing...

By Daniella Parra Health tech company Helfie AI has appointed Stefan Kulik as Chief Operating Officer and Rania Awad as Chief Strategy Officer, strengthening its leadership team as it prepares for the global consumer launch of its AI-powered mobile health...

By Daniella Parra Recordati, an international pharmaceutical company said its consolidated net revenue rose 12% to  €1.3 billion in the first half of 2025. Rare Diseases revenue was €515.7 million for the first half of 2025, up 29.2% as compared...

By Karen Roman NanoCell Therapeutics, Inc. said it published data in the Journal for ImmunoTherapy of Cancer showing the results of NCtx, its targeted lipid nanoparticle delivery system. The study is the first successful demonstration of non-viral DNA delivery to...

By Karen Roman ReAlta Life Sciences, Inc. said it designated Ellen Lubman as Chief Business Officer to supervise business development, capital formation and corporate strategy. Ms. Lubman has nearly 25 years of experience across small to large-cap private and public...

By Daniella Parra ReAlta Life Sciences said Pegtarazimod is being evaluated in a Phase 2 trial across 13 U.S. NICUs for newborns with moderate to severe neuroinflammation in HIE. The company said that newborn rats treated with pegtarazimod after oxygen...

  By Daniella Parra Lisata Therapeutics said it has been granted a new composition of matter patent for its lead drug candidate, certepetide, offering the highest level of IP protection by covering the drug’s unique chemical structure, how it’s made,...

By Daniella Parra Inventiva said Dr. Jason Campagna has been named President of R&D and Chief Medical Officer as Inventiva advances lanifibranor, its lead candidate for MASH, with topline Phase 3 results from the NATiV3 trial expected in the second...

By Karen Roman Ascentage Pharma Group International (Nasdaq: AAPG) said China’s National Medical Products Administration (NMPA) approved the use of lisaftoclax for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. The authorization makes lisaftoclax the first inhibitor of...